Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Developmental follow-up, surveillance and support at the age of 4 years: a best practice guide from the British Association for Neonatal Neurodevelopmental Follow-Up.

Archives of disease in childhood. Fetal and neonatal editionยท2026
Same author

Factors associated with the adoption of the WHO Package of Essential Non-Communicable Diseases (PEN) Protocol 1 in primary healthcare settings in Nepal: a cross-sectional study.

BMJ openยท2025
Same author

Successful serial plasmapheresis for solar urticaria, a case report and literature review.

The Journal of dermatological treatmentยท2024
Same author

Capture-based targeted sequencing using a T-cell control in myeloid malignancies and idiopathic cytopenias.

British journal of haematologyยท2024
Same author

Laboratory practice is central to earlier myeloma diagnosis: Utilizing a primary care diagnostic tool and laboratory guidelines integrated into haematology services.

British journal of haematologyยท2024
Same author

Investigation and management of the monoclonal gammopathy of undetermined significance: A British Society for Haematology Good Practice Paper.

British journal of haematologyยท2023

Related Experiment Video

Updated: Jun 12, 2026

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

Thrombopoietic agents.

Roberto Stasi1, Jenny Bosworth, Elizabeth Rhodes

  • 1Department of Haematology, St George's Hospital, London, United Kingdom. Roberto.Stasi@stgeorges.nhs.uk

Blood Reviews
|May 25, 2010
PubMed
Summary
This summary is machine-generated.

Second-generation thrombopoiesis-stimulating agents, like romiplostim and eltrombopag, offer new treatments for thrombocytopenia. These novel molecules avoid issues seen with earlier thrombopoietin (TPO) therapies.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Related Experiment Videos

Last Updated: Jun 12, 2026

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Area of Science:

  • Hematology
  • Pharmacology
  • Oncology

Background:

  • Thrombopoietin (TPO) is crucial for platelet production, binding to the TPO receptor on megakaryocytes.
  • First-generation TPO agents faced development halts due to neutralizing auto-antibodies causing thrombocytopenia.
  • Second-generation agents possess distinct properties and lack homology with endogenous TPO, mitigating prior risks.

Purpose of the Study:

  • To review the development and application of second-generation thrombopoiesis-stimulating agents.
  • To highlight the efficacy of novel agents in treating various thrombocytopenic conditions.

Main Methods:

  • Review of clinical trial data (Phase II and III) for novel thrombopoietic agents.
  • Analysis of pharmacological properties and safety profiles of second-generation molecules.
  • Examination of marketing authorizations and ongoing studies in diverse patient populations.

Main Results:

  • Romiplostim and eltrombopag have successfully completed Phase III trials for primary immune thrombocytopenia.
  • These agents have received marketing authorization for treating primary immune thrombocytopenia.
  • Ongoing trials are exploring their use in chemotherapy-induced thrombocytopenia, chronic liver disease, and myelodysplastic syndromes.

Conclusions:

  • Second-generation thrombopoietic agents represent a significant advancement over first-generation therapies.
  • Novel agents like romiplostim and eltrombopag show promise for managing various thrombocytopenic disorders.
  • Further clinical development is underway for other emerging thrombopoietic growth factors.